LAT1 may be leveraged for the delivery of anti-tumor drugs or as a carrier for radiopharmaceuticals [19,35], or directly targeted for inhibition due to its epitope specificity and role in cancer proliferation [36]. Here, SLC7A5 is linked to cancer.